<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217203</url>
  </required_header>
  <id_info>
    <org_study_id>IPH2101-202</org_study_id>
    <nct_id>NCT01217203</nct_id>
  </id_info>
  <brief_title>Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse</brief_title>
  <acronym>KIRIMID</acronym>
  <official_title>Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the clinical study is to evaluate, in patients who experience a&#xD;
      first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101&#xD;
      combined with lenalidomide&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with Dose Limiting Toxicity (DLT) at each dose level</measure>
    <time_frame>1 year</time_frame>
    <description>safety of IPH2101 combined with lenalidomide at different dose levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess response rate of the combination</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Patients With Multiple Myeloma Experiencing a</condition>
  <condition>First or Second Relapse</condition>
  <arm_group>
    <arm_group_label>IPH2101 and lenalinomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2101 combined to lenalidomide</intervention_name>
    <description>Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)&#xD;
Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)</description>
    <arm_group_label>IPH2101 and lenalinomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent obtained before any trial-related activities&#xD;
&#xD;
          2. Progressive disease or relapse of multiple myeloma (according to the IMWG definition)&#xD;
             after one or two prior therapeutic treatments or regimens for multiple myeloma that&#xD;
             achieved a response duration of at least 6 months&#xD;
&#xD;
          3. Prior therapeutic treatment regimens may have included Thalidomide and Lenalidomide.&#xD;
             Regarding patients previously treated by Lenalidomide, only patients who achieved at&#xD;
             least Partial Response duration of at least 6 months can be included. The patient must&#xD;
             not have discontinued treatment due to Lenalidomide intolerance.&#xD;
&#xD;
          4. Measurable disease, as indicated by one or more of the following:&#xD;
&#xD;
               -  Serum M-protein ≥ 0.5 g/dL If Serum Protein Electrophoresis is felt to be&#xD;
                  unreliable for routine M-protein measurement (particularly for patients with IgA&#xD;
                  MM), then quantitative immunoglobulin levels can be accepted).&#xD;
&#xD;
               -  Urine Bence-Jones protein ≥ 200 mg/24 h&#xD;
&#xD;
               -  Involved serum Free Light Chains (sFLC) level ≥ 10 mg/dl ( ≥ 100 mg/l) provided&#xD;
                  sFLC ratio is abnormal (&lt;0.26 or &gt;1.65)&#xD;
&#xD;
          5. ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          6. Clinical laboratory values at screening&#xD;
&#xD;
               -  Calculated creatinine clearance (according to MDRD) &gt; 60 ml/min&#xD;
&#xD;
               -  Platelet ≥ 75 x 109 /l for patients with &lt; 50% BM plasma cells, and ≥ 30 x 109 /l&#xD;
                  for patients with &gt; 50% BM plasma cells&#xD;
&#xD;
               -  ANC &gt; 1 x 109 /l&#xD;
&#xD;
               -  Bilirubin levels &lt; 1.5 ULN ; ALT and AST &lt; 3 ULN (grade 1 NCI)&#xD;
&#xD;
          7. Females of childbearing potential (FCBP)† must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to&#xD;
             and again within 24 hours of prescribing Lenalidomide (prescriptions must be filled&#xD;
             within 7 days) and must either commit to continued abstinence from heterosexual&#xD;
             intercourse or begin TWO acceptable methods of birth control, one highly effective&#xD;
             method and one additional effective method AT THE SAME TIME, at least 28 days before&#xD;
             she starts taking Lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men&#xD;
             must agree to use a latex condom during sexual contact with a FCBP even if they have&#xD;
             had a successful vasectomy&#xD;
&#xD;
          8. All study participants must be registered into the mandatory RevAssist® program, and&#xD;
             be willing and able to comply with the requirements of RevAssist®.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years or &gt; 80 years&#xD;
&#xD;
          2. Non secreting multiple myeloma or non measurable disease (&lt; 0.5 g /dL M-Protein in&#xD;
             serum or &lt; 200 mg urinary M-protein / 24 h or &lt;10 mg/dl involved sFLC)&#xD;
&#xD;
          3. Life-threatening conditions related or not to MM relapse&#xD;
&#xD;
          4. Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking Lenalidomide)&#xD;
&#xD;
          5. Known hypersensitivity to thalidomide or IMiD®.&#xD;
&#xD;
          6. Use of any investigational agent within the last month&#xD;
&#xD;
          7. Treatment by systemic corticosteroids (except inhaled corticosteroids) or chemotherapy&#xD;
             (including consolidation and maintenance) within the last month (use of biphosphonates&#xD;
             is permitted)&#xD;
&#xD;
          8. Radiotherapy within the last month&#xD;
&#xD;
          9. Primary or associated amyloidosis&#xD;
&#xD;
         10. Peripheral neuropathy of grade ≥ 3 according to the CTCAE of the NCI&#xD;
&#xD;
         11. Abnormal cardiac status with any of the following&#xD;
&#xD;
               -  NYHA stage III or IV congestive heart failure&#xD;
&#xD;
               -  myocardial infarction within the previous 6 months&#xD;
&#xD;
               -  cardiac arrhythmia remaining symptomatic despite treatment&#xD;
&#xD;
         12. Current active infectious disease or positive serology for HIV, HCV or positive Hbs&#xD;
             Antigen&#xD;
&#xD;
         13. History of or current auto-immune disease&#xD;
&#xD;
         14. History of other active malignancy within the past 5 years (apart from basal cell&#xD;
             carcinoma of the skin, or in situ cervix carcinoma)&#xD;
&#xD;
         15. Serious concurrent uncontrolled medical disorder&#xD;
&#xD;
         16. History of allograft or solid organ transplantation&#xD;
&#xD;
         17. Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
         18. Inability to comply with an antithrombotic regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Benson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Comprehensive Cancer Center - Columbus OH - USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greensville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

